Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Our Impact

The Bionics Institute has long been at the forefront of translating medical device concepts into clinical reality.

Track record of commercialisation

Bionics Institute founder, Professor Graeme Clark led the team that created Australia’s cochlear implant, commercialised by Cochlear Pty Ltd.

Bionics Institue researchers also designed the electrodes used in Australia’s first-generation bionic eye prototype implanted in clinical trials in 2018, and work closely with Bionic Vision Technologies on further research.

Since then, Bionics Institute research has led to the creation of three spin-off companies:

Epi-Minder was established in 2018 to commercialise an epilepsy seizure monitoring device.

DBS Tech was established in 2019 to commercialise an adaptive deep brain stimulation system for Parkinson’s disease.

Neo-Bionica a specialised medical device design and manufacturing company, was established in 2021 as a joint initiative of the Bionics Institute and the University of Melbourne.

Our commercialisation pipeline

The Bionics Institute also has a number of research projects in the pipeline towards commercialisation:

Vagus nerve stimulation device to provide a drug-free treatment for autoimmune and chronic diseases, such as Crohn’s disease and rheumatoid arthritis.

A new hearing test called EarGenie, that will enable audiologists to choose and tailor the best type of hearing device at an earlier age than currently possible.

Revolutionary nanotechnology to restore hearing using therapeutics.

An objective measure of tinnitus to improve diagnosis and treatments.

Personalising transcranial magnetic stimulation treatment to fight memory loss in Alzheimer’s disease.

Our funding model

Our impact is underpinned by our funding model that allows for different income streams at each stage of the product lifec-cycle.

Tax deductible donations are vital to fund early-stage, conceptual research and initial research trials.

Impact investment and equity investment enables us to turn ground-breaking research into clinical reality.

Impact investment opportunties

We have a number of impact investment opportunities available to take our pipeline projects to the next stage of commercialisation.

To find out more, get in touch.

Research Articles